Skip to content

Effect of ergocalciferol supplementation on peritonitis among peritoneal dialysis : a randomized controlled trial.

Effect of ergocalciferol supplementation on peritonitis among peritoneal dialysis : a randomized controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20191109001
Enrollment
200
Registered
2019-11-09
Start date
2020-01-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

continuous ambulatory peritoneal dialysis patients CAPD Peritonitis vitamin d deficiency

Interventions

oral ergocalciforol 40&#44
000 iu/wk every 2 weeks&#44
totally 20 weeks&#44
total dose of ergocalciferol 800&#44
000 iu standard treatment for CAPD and other comorbities ,standard treatment for CAPD and other comorbities
Experimental Drug,No Intervention No treatment
oral ergocalciferol and standard treatment ,standard treatment

Sponsors

Dialysis unit, department of medicine, kalasin hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: ESRD on CAPD and stable run CAPD more than one month.

Exclusion criteria

Exclusion criteria: previous vitamin d intake previous peritonitis 3 months active cancer hypercalcemia with serum calcium >10.5 mg/dL iPTH < 50 pg/ml

Design outcomes

Primary

MeasureTime frame
peritonitis event 24 weeks Logrank test

Secondary

MeasureTime frame
Death from any cause infection 24 weeks Logrank test ,CVD death 24 weeks logrank test ,secondary hyperparathyroidism 24 weeks Z&#45;test ,falling 24 weeks Z&#45;test ,fracture 24 weeks Z&#45;test ,depression 24 weeks Z&#45;test ,anemia 24 weeks Z&#45;test

Countries

Thailand

Contacts

Public Contactkrittapong somboon

kalasin hospital

krittapong_medicine@hotmail.com0863343643

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026